MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model.
MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a Netherlands-based company specializing in commercially available human renal cells, to distribute its products in the US as well as develop a new in vitro kidney model.
MatTek will act as a US-based distributor for Cell4Pharma’s ciPTEC renal cells, making them available to their broad customer base in the life sciences and diversifying their commercially available cell types. Cell4Pharma’s ciPTEC technology is a human renal cell line that mimics the proximal tubule of the kidney, a common target for drug-induced kidney injury. The cells are currently used by researchers in monolayer culture as a preclinical screening tool by pharmaceutical developers to evaluate potential negative impacts to the kidney.
MatTek’s goal is to create a more complex, 3-dimensional model of the human kidney to further enhance the in vitro capabilities and provide an even more accurate and predictive testing method for researchers within ADME tox market, estimated to be $6 billion USD according to ReportLinker. MatTek anticipates research and development to take 1 year and to have a finished product on the market within 18 months.
“MatTek has really pioneered the field of lab-grown tissues for preclinical testing, and we’ve had great success in developing multiple organ systems that have been shown to produce results much closer to live human responses than traditional animal testing,” said Kevin Causey, vice president of business development for MatTek. “We’ve already created a large selection of reliable lab-grown human skin, ocular, oral, airway, and digestive system tissues, and it’s a natural progression to move onto organs like the kidney to fill those gaps in available research systems.”
“The strategic partnership with MatTek is in line with our goal to accelerate our growing global network of strategic partners. This partnership supports our mission to support human-relevant research by providing synergistic life science products and services,” said Ron Byron, CEO of Cell4Pharma.
For further information, please contact:
Avijit Minocha, Head of Marketing, BICO
Phone (US): +1 (617) 637 5372
Email: akm@cellink.com
This information was submitted for publication, through the agency of the contact persons set out above, on March, 23, 2022 at 14:00 (CET).
About MatTek
Founded in 1985, MatTek Life Sciences began producing three-dimensional human tissue models as reliable replacements for animal testing. MatTek’s physiologically advanced tissue models empower companies in the cosmetics, chemical, and pharmaceutical industries to achieve their goals of non-animal testing while lowering preclinical costs and providing human-relevant results. With locations in the US and Europe, today MatTek’s offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical cultureware.
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
About Cell4Pharma
Cell4Pharma’s ciPTEC is a Dutch Bio- technology company, that developed a range of cell-based assays, including CiPTEC a human conditionally immortalized proximal tubular epithelial cell line, used for pre-clinical toxicology studies. Cell4Pharma envisions a world without a risk for renal toxicity for compounds entering clinical stages of drug development. Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation.
